J. Heuvel

发表

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours

N. Brünner, J. Foekens, J. Klijn, 2001, British Journal of Cancer.

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.

N. Brünner, C. Sweep, G. Brugal, 1998, British Journal of Cancer.

A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols

A. Geurts-Moespot, J. Heuvel, T. Benraad, 1997, The International journal of biological markers.

Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response

J. Bussink, P. Span, I. Nagtegaal, 2011, Breast Cancer Research.

Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group.

A. Sieuwerts, J. Martens, P. Span, 2009, European journal of cancer.

Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.

N. Brünner, J. Foekens, C. Sweep, 1996, European journal of cancer.

Complexes between urokinase‐type plasminogen activator and its receptor in blood as determined by enzyme‐linked immunosorbent assay

N. Brünner, L. Beex, F. Sweep, 1998, International journal of cancer.

High-Performance LiquidChromatography of 1251-Labeled MouseEpidermal Growth FactorRadioiodinated by Six DifferentMethods

J. Foekens, J. Heuvel, H. Ross, 1992 .

High-performance liquid chromatography of 125I-labeled mouse epidermal growth factor radioiodinated by six different methods.

J. Foekens, J. Heuvel, T. Benraad, 1992, Clinical chemistry.

Six methods for direct radioiodination of mouse epidermal growth factor compared: effect of nonequivalence in binding behavior between labeled and unlabeled ligand.

J. Foekens, J. Heuvel, T. Benraad, 1991, Clinical chemistry.

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

J. Foekens, J. Klijn, C. Sweep, 1999, British Journal of Cancer.

GATA transcription factors in testicular adrenal rest tumours

Lee B. Smith, P. Span, F. Sweep, 2016, Endocrine connections.

ELISA for complexes of urokinase‐type and tissue‐type plasminogen activators with their type‐1 inhibitor (uPA∼PAI‐1 and tPA∼PAI‐1)

F. Sweep, J. Heuvel, T. Benraad, 1999, International journal of cancer.

Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis

C. Sweep, P. Span, J. Heuvel, 2004, Annals of the rheumatic diseases.

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

J. Foekens, J. Klijn, C. Sweep, 1999, British Journal of Cancer.

Quality control in quantitation of components of the plasminogen activator system in tumour extracts

C. Sweep, A. Geurts-Moespot, J. Witte, 1996 .

Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR.

C. Sweep, P. Span, J. Schalken, 2002, The Journal of endocrinology.

Molecular beacon reverse transcription-PCR of human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in breast cancer.

C. Sweep, P. Span, L. Beex, 2003, Clinical chemistry.

Receptor-positive Human Primary Breast Cancers Predominantly Confined to the Subgroup of Estradiol Epidermal Growth Factor Receptor-negative Tumors Are Updated

A. Geurts-Moespot, J. Heuvel, T. Benraad, 2006 .

Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers.

L. Beex, A. Geurts-Moespot, J. Heuvel, 1991, Cancer research.

Six Methodsfor DirectRadioiodination of MouseEpidermalGrowthFactor Compared:Effectof Nonequivalence in BindingBehaviorbetweenLabeledand UnlabeledLigand

J. Heuvel, H. Ross, C. Kienhuis, 1991 .

Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP‐3 is associated with adjuvant endocrine therapy success

P. Span, R. Lindberg, L. Beex, 2004, The Journal of pathology.

Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?

J. Foekens, P. Span, F. Sweep, 2006, Clinical chemistry.

Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer

C. Sweep, P. Span, L. Beex, 2002, Oncogene.

Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.

J. Foekens, M. Watson, P. Span, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E1AF Expression Levels are not Associated with Prognosis in Human Breast Cancer

C. Sweep, P. Span, L. Beex, 2003, Breast Cancer Research and Treatment.